Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,743 recruiting studies in this area right now.
By phase
- Not applicable9,868
- Phase 24,491
- Phase 12,735
- Phase 1/Phase 21,687
- Phase 31,413
- Phase 2/Phase 3284
- Phase 4265
Top conditions
- Breast Cancer1,244
- Prostate Cancer661
- Cancer657
- Colorectal Cancer499
- Lung Cancer431
- Ovarian Cancer342
- Multiple Myeloma331
- Gastric Cancer302
- Pancreatic Cancer295
- Acute Myeloid Leukemia290
- Hepatocellular Carcinoma286
- Solid Tumor254
- Advanced Solid Tumor251
- Cervical Cancer233
- Head and Neck Cancer229
- Endometrial Cancer208
- Esophageal Cancer197
- Advanced Solid Tumors196
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University321
- National Cancer Institute (NCI)292
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- Mayo Clinic237
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca131
- University Health Network, Toronto125
Where studies are running
- California1,433
- Texas644
- Arizona513
- Florida434
- Alabama418
- New York410
- Massachusetts341
- Maryland330
- New Jersey266
- Pennsylvania238
Recruiting studies20,743 total
- NCT06953999RecruitingPhase 3
Testing immunotherapy plus chemo for metastatic pancreatic cancer
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Harbin, HeilongjiangAges 18–75 - NCT06954077RecruitingPhase 1
BL-M09D1 for advanced gastrointestinal and other solid tumors
This trial tests a new drug, BL-M09D1, for people with advanced or metastatic gastrointestinal or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT06954233Recruiting
Urination and erections after lymph node surgery for testicular cancer
This study looks at how removing lymph nodes in the back of the belly for testicular cancer affects urination and erectile function. It may help patients understand what to expect after this surgery.
Krakow, MalopolskaAges 18 years+ - NCT06954246RecruitingPhase 3
New drug vs. doctor’s choice for relapsed small cell lung cancer
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
ShanghaiAges 18 years+ - NCT06954337Recruiting
Telehealth cancer care at home study for breast or prostate cancer
This trial tests if telehealth (video or phone visits) can be a safe and effective way to manage your cancer care at home. It is for people with breast or prostate cancer who have had at least three prior visits with their medical oncologist at Memorial Sloan Kettering.
Basking Ridge, New JerseyAges 18 years+ - NCT06954467RecruitingPhase 2
Two immunotherapy drugs for advanced liver cancer
This study tests two new immunotherapy drugs (JS207 and JS007) as a first treatment for advanced liver cancer. It might be an option if you have not had any prior cancer medicine and your liver tumor is not blocking the main portal vein.
Hefei, AnhuiAges 18 years+ - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT06954584RecruitingPhase 3
Fluzoparib with or without bevacizumab or diet for advanced ovarian cancer
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
Wuhan, HubeiAges 18 years+ - NCT06954623Recruiting
Partial breast re-irradiation for breast cancer recurrence
This trial tests a second round of radiation to just part of the breast for women who had a previous lumpectomy and radiation, and now have a small, early-stage cancer or DCIS in the same breast. The goal is to see if a focused re-treatment is safe and effective.
HeidelbergAges 18 years+ - NCT06954636Recruiting
Smell test to predict glioblastoma outcomes (newly diagnosed)
This study looks at whether a simple smell test can help predict how glioblastoma will progress. It is for people who are newly diagnosed and have not started treatment yet.
EssenAges 18 years+ - NCT06954805RecruitingPhase 2
Study of ctDNA in PTLD after transplant
This trial looks at a blood test (ctDNA) to track post-transplant lymphoproliferative disorder (PTLD). It tests how well ctDNA measures treatment response and may help guide future care.
Stanford, CaliforniaAges 15 years+ - NCT06954831RecruitingPhase 2
Short-course radiation for early-stage breast cancer
This trial tests a shorter, more intense radiation schedule for people with stage I-III breast cancer after lumpectomy. It aims to find if giving a higher daily dose over fewer sessions is safe and effective.
Arcadia, CaliforniaAges 40 years+ - NCT06954961RecruitingPhase 3
Study of D-0502 for ER+ HER2- advanced breast cancer
This trial tests an oral drug called D-0502 for people with a specific type of advanced breast cancer (ER-positive, HER2-negative). It is for those whose cancer has returned or worsened after hormone therapy, and it may be an option before trying more chemotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06955156RecruitingPhase 2
Trilaciclib with immunotherapy and chemo for early TNBC
This trial tests a new drug combination for people with locally advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if adding trilaciclib to standard chemo and immunotherapy works better before surgery.
BeijingAges 18–75 - NCT06955208Recruiting
Using MRI to Measure Meningioma Stiffness Before Surgery
This study uses a special MRI technique called 3D MRE (magnetic resonance elastography) to measure how stiff a meningioma tumor is. The goal is to see if the stiffness can help predict the tumor’s type and characteristics before surgery.
Shenyang, LiaoningAges 18–80 - NCT06955702Recruiting
Cryotherapy to Prevent Eyelash Loss from Chemo
This trial tests if cooling the eyelids during chemotherapy can prevent eyelash loss in women with newly diagnosed breast cancer. It is for those who have not yet started treatment.
Santander, CantabriaAges 18 years+ - NCT06955988RecruitingPhase 1
Safety and early results of AST2303 for advanced lung cancer
This trial tests a new oral drug, AST2303 (ABK3376), in people with advanced non-small cell lung cancer that has not responded to other treatments. It aims to see if the drug is safe and whether it can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06956001RecruitingPhase 3
Testing firmanertinib vs chemo for first-line lung cancer with specific EGFR mutations
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06956027Recruiting
Ultrasound study of Dupuytren's disease nodules
This study uses ultrasound to look at Dupuytren's disease nodules and track changes over 6 months. It may help doctors understand which nodules are active and need treatment.
Leuven, Vlaams-BrabantAges Any age - NCT06956040Recruiting
Family doctor involvement in lung cancer screening
This study tests whether having your family doctor offer you a lung cancer screening scan (low-dose CT) can help find cancer early. You may qualify if you are a current or former heavy smoker and can travel to a Paris hospital for the scan.
ParisAges 50–74 - NCT06956144Recruiting
CAIX-targeted PET scan for kidney cancer
This trial uses a special PET scan that targets a protein (CAIX) often found in kidney cancer cells. It helps doctors see the cancer more clearly, which may guide better treatment decisions.
XiamenAges 18–74 - NCT06956391RecruitingPhase 2
Ultra-low dose PET scan study using FDG
This study tests if a very low dose of a standard PET scan tracer (FDG) can produce clear images. It may help people who need a PET scan but are concerned about radiation exposure.
Englewood, New JerseyAges 18–120 - NCT06956690RecruitingPhase 1/Phase 2
Testing HMBD-501 for HER3-positive advanced solid tumors
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06956781Recruiting
Finding the best treatment for childhood PTSD
This study tests different ways to help children ages 8-17 who have PTSD after a traumatic event. It looks at how to best support both the child and their caregiver through therapy and surveys.
Rochester, New YorkAges 8–17
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,743 recruiting oncology studies from the U.S. registry right now, out of 32,463 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.